注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Globeimmune Inc是一家生物製藥公司。該公司專註於開發基於其Tarmogen平臺的治療癌癥和傳染病的產品。該公司的Tarmogen平臺通過刺激稱為T細胞的白血球亞群來激活免疫系統,從而摧毀受感染或惡性細胞,這與主要刺激抗體產生的傳統疫苗不同。Tarmogens還能減少調節性T細胞的數量和功能,從而進一步促成抗原特異性細胞免疫反應。該公司有兩個以上的Tarmogen候選產品正在進行臨床評估,用於傳染病和多種癌癥適應癥。該公司的腫瘤學候選產品包括GI-6301, GI-6207和GI-4000。該公司的傳染病候選產品包括GS-4774, GI-19000, GI-2010和GI-18000。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Richard C. Duke | - | 1996 | Scientific Founder & Member of Scientific Advisory Board |
Donald Bellgrau | - | 1996 | Scientific Founder & Chairman of The Scientific Advisory Board |
Bruce Walker | - | - | Member of Scientific Advisory Board |
Francis V. Chisari | - | 2005 | Member of Scientific Advisory Board |
Alan P. Venook | - | - | Member of Scientific Advisory Board |
Robert Peach | 66 | 2006 | Member of Scientific Advisory Board |
Edward Mocarski | - | 2004 | Member of Scientific Advisory Board |
Timothy C. Rodell | 71 | 2003 | Director |
Paul A. Bunn | 76 | - | Member of Scientific Advisory Board |
Carl H. June | 68 | - | Member of Scientific Advisory Board |
Charles A. Dinarello | 79 | - | Member of Scientific Advisory Board |
Jules Harris | - | 2006 | Member of Scientific Advisory Board |
Teresa Brentnall | - | 2004 | Member of Scientific Advisory Board |
Robert T. Schooley | - | - | Member of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核